BioSpace News Archive

Bio NC

Study Showcases how Medical Affairs Provides Value to External Stakeholders Such as Payers and Specialty Pharmacies

Medical Affairs has long been a key function within the pharmaceutical industry because of its role in providing medical information to external stakeholder groups.

June 15, 2018
·
2 min read
Policy

Indivior Is Granted Temporary Restraining Order

Indivior PLC announced that the U.S. District Court for the District of New Jersey has granted Indivior a temporary restraining order (TRO) that compels Dr. Reddy’s (DRL) to immediately cease its launch activities related to SUBOXONE® Film.

June 15, 2018
·
8 min read
Policy

Calif. Appeals Court Suspends Lower Court Ruling, Reinstates End of Life Option Act

Ruling Allows Terminally Ill Californians to Use Law to Die Peacefully

June 15, 2018
·
6 min read
Drug Development

As Treatments Await FDA Ruling, Researchers Discover ‘Key Players’ in Early-Onset Parkinson’s Disease

While pharma and biotech researchers have been driving forward with therapies aimed at helping Parkinson’s disease patients, medical researchers have identified “unexpected new key players” in the development of early-onset Parkinson’s disease, called Parkinsonism.

June 15, 2018
·
4 min read
·
Alex Keown
Bio NC

June 15th Research Roundup: Some of the Top Research Stories of the Week

From CRISPR to spider silk there are some great scientific research stories out this week.

June 15, 2018
·
5 min read
·
Mark Terry
Drug Development

Anemia Patients Benefit from bluebird’s LentiGlobin Gene Therapy, Trial Data Shows

Bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.

June 15, 2018
·
3 min read
·
Alex Keown
Drug Development

Selecta Unveils Expanded Positive Clinical Data for its Gout Treatment

Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage trial that showed a significant reduction of serum uric acid at 12 weeks.

June 15, 2018
·
2 min read
·
Alex Keown
Drug Development

Motif Completes Rolling NDA for Iclaprim

Shares of Motif Bio plc shot up late Thursday after the company announced it had completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for its acute bacterial skin and skin structure infections (ABSSSI) treatment, iclaprim.

June 15, 2018
·
2 min read
·
Alex Keown
Drug Development

Epizyme Posts Positive Interim Data for Follicular Lymphoma Treatment, Despite Partial Clinical Hold

Despite some of the troubles Epizyme has seen with its lead drug candidate tazemetostat, including a partial clinical hold placed by the U.S. Food and Drug Administration, the company is pushing forward with positive interim data presented at the 23rd Congress of the European Hematology Association.

June 15, 2018
·
3 min read
·
Alex Keown
Genetown

AMAG Pharmaceuticals Divests Cord Blood Registry for $530 Million

AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners. Focus will now be on pharmaceutical products.

June 15, 2018
·
2 min read
·
Alex Keown